The phase III EMPOWER-Lung 3 study enrolled advanced NSCLC patients irrespective of their PD-L1 expression level and found that cemiplimab plus chemotherapy was associated with clinically and statistically significant improvements in PFS and OS compared with chemotherapy alone [139]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.